VIRIDIAN THERAPEUTICS INC (VRDN)

Notable Monday Option Activity: HUN, RIVN, VRDN

The market is buzzing with gapping stocks on Monday. Let's uncover which stocks are experiencing notable gaps during today's session.

Which stocks are gapping on Monday?

Viridian Therapeutics Skyrockets After Besting Amgen In Thyroid Eye Disease

The company's drug led to an improvement in diplopia, or double vision, an area where Amgen's Tepezza hasn't worked.

Discover the top movers in Monday's pre-market session and stay informed about market dynamics.

Let's have a look at what is happening on the US markets before the opening bell on Monday. Below you can find the top gainers and losers in today's pre-market session.

Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease

Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024

Viridian Therapeutics Enters Oversold Territory (VRDN)

Investors Pick Up VRDN Even Lower Than Its Secondary Stock Offering

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Notable Monday Option Activity: HEAR, PD, VRDN

Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tuesday 10/1 Insider Buying Report: VRDN, ENGN

Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock

Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock

Notable Tuesday Option Activity: BOOT, VRDN, BYON

Viridian Therapeutics (VRDN) Shares Cross Above 200 DMA

Viridian Spikes On A 'Bull-Case Scenario' For Eye Drug Considered Amgen Rival

The results are also promising for the next-generation version of that drug.

Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease

Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VRDN Stock Earnings: Viridian Therapeutics Misses EPS, Misses Revenue for Q2 2024

VRDN stock results show that Viridian Therapeutics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.

Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense

Biogen has $8 billion to $10 billion in dry powder for acquisitions. Here are three names the company could examine.

3 Small-Cap Stocks With Explosive 2X Growth Potential

Discover three top high-growth small-cap stocks, fueled by potential rate cuts and promising prospects in the second half of 2024.